Zoetis Investors Face Losses as Securities Class Action Proceeds

The legal action, spearheaded by Levi & Korsinsky, LLP, targets a period of significant volatility for the animal health firm. On May 7, 2026, Zoetis stock plummeted by $23.91 per share following disclosures that veterinarian prescription volume and clinic patient traffic had deteriorated. The lawsuit alleges that management failed to disclose the impact of increasing price sensitivity among pet owners and the rising influence of lower-cost competitors like Elanco.

Central to the complaint is the performance of the company's Companion Animal segment, which accounts for roughly 70% of total revenue. Plaintiffs contend that demand for key products—including Librela, Simparica Trio, Apoquel, and Cytopoint—was artificially bolstered by misleading narratives about growth durability. While the company maintained a positive outlook, internal data reportedly showed a decline in veterinarian confidence, partially driven by safety concerns and the emergence of rival treatments. Investors seeking to participate as lead plaintiffs have until July 27, 2026, to file with the court. Participation in such actions typically operates on a contingency basis, requiring no upfront legal fees from shareholders.